2. Academic Validation
  3. Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core

Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core

  • Bioorg Med Chem Lett. 2011 Oct 15;21(20):6122-5. doi: 10.1016/j.bmcl.2011.08.028.
Robert L Dow 1,  Melissa Andrews,  Gary E Aspnes,  Gayatri Balan,  E Michael Gibbs,  Angel Guzman-Perez,  Kapil Karki,  Jennifer L Laperle,  Jian-Cheng Li,  John Litchfield,  Michael J Munchhof,  Christian Perreault,  Leena Patel
Affiliations

Affiliation

  • 1 Pfizer Global Research and Development, Groton, CT 06340, USA. robert.l.dow@pfizer.com
PMID: 21908190 DOI: 10.1016/j.bmcl.2011.08.028
Abstract

A novel series of potent DGAT-1 inhibitors was developed originating from the lactam-based clinical candidate PF-04620110. Incorporation of a dioxino[2,3-d]pyrimidine-based core afforded good alignment of pharmacophore features and resulted in improved passive permeability. Development of an efficient, homochiral synthesis of these targets facilitated confirmation of predictions regarding the stereochemical-dependence of DGAT-1 inhibition for this series. Compound 10 was shown to be a potent inhibitor of human DGAT-1 (10 nM) and to suppress triglyceride synthesis at oral doses of <3mg/kg.

Figures
Products